Showing results (321-330 of 341) with videos related to
Sort By:
Pageof 35
Scientific Reports|December 7, 2021
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in TaiwanChung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, et al.Journal of Viral Hepatitis|September 13, 2025
Impact of Concurrent Steatotic Liver Disease and Chronic Hepatitis B on Treatment Response to Nucleos(t)ide AnalogsAngela Chau, Jie Li, Dae Won Jun, et al.The Lancet. Gastroenterology & Hepatology|May 23, 2025
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trialYinghong Shi, Guohong Han, Jian Zhou, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|August 21, 2024
Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registryTyng-Yuan Jang, Chung-Feng Huang, Te-Sheng Chang, et al.Infectious Diseases and Therapy|April 28, 2024
Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in TaiwanChun-Chi Yang, Chung-Feng Huang, Te-Sheng Chang, et al.Hepatology International|January 21, 2024
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from TaiwanMing-Lung Yu, Chi-Ming Tai, Lein-Ray Mo, et al.Liver International : Official Journal of the International Association for the Study of the Liver|March 3, 2021
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in TaiwanChi-Yi Chen, Chung-Feng Huang, Pin-Nan Cheng, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 6, 2022
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in TaiwanChing-Chu Lo, Chung-Feng Huang, Pin-Nan Cheng, et al.Clinical and Molecular Hepatology|January 9, 2024
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry programMing-Ying Lu, Chung-Feng Huang, Chao-Hung Hung, et al.Hepatology International|February 27, 2025
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver diseaseMohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, et al.Pageof 35